TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Febratinib.

Authors: Wu D, Yang XO

PMID: 32205092 PMCID: PMC7156211 DOI: 10.1016/j.jmii.2020.03.005

Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Keywords: COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17.

Source: https://pubmed.ncbi.nlm.nih.gov/32205092/
Archive: https://archive.ph/CLQZ8